Recently added

CD4+ and CD8+lymphocyte distribution among healthy Kenyans

Anzala, O; Manyonyi, GO; Jaoko, W; Bashir, M; Oyugi, J; Bwayo, J (University of NairobiSchool of Medicine, 2004)

Reasons for declining enrolment among eligible volunteers in a phase II HIV vaccine trial in Kenya

Wakasiaka, S; McBride, M; Omosa, GM; Bwayo, JJ; Ndinya-Achola, A; Jaoko, WG; Anzala, O; Ogutu, H; Waruinge, W (University of NairobiSchool of Medicine, 2004)

Safety profile of DNA and MVA HIV preventive vaccines

Jaoko, WG; Manyonyi, GO; Bhatt, KM; Wakasiaka, S; Ogutu, H; Bashir, FM; Anzala, AO; Oyugi, M; Schmidt, C; Ongeri, M; Waruingi, W; Nyange, J; Indangasi, J; Bwayo, JJ; Ndinya-Achola, J; Mbori-Ngacha, D; Ngugi, E; Fast, P (University of NairobiSchool of Medicine, 2004)

Income Inequality in Kenya: Some Technical Perspectives. Policy Paper prepared for Society for International Development, Nairobi

Gor, SO (College of Humanities and Social Sciences, 2007)

Safety and immunogenicity of DNA and MVA HIVA vaccines in Phase-1 vaccine trials in Nairobi, Kenya

Jaoko, WG; Omosa, G; Bhatt, K; Matu, L; Ogutu, H; Wakasiaka, S; Odada, J; Anzala, O; Bashir, F; Oyaro, M; Indangasi, J; Ndinya-Achola, J; Schmidt, C; Hanke, T; McMichael, A; Fast, P; Bwayo, J (University of NairobiSchool of Medicine, 2004)

Training Facilitators of Examinations Workshop for the School of Biological Sciences

Digolo, Patrick Obonyo Ochieng. (University of NairobiDepartment of Education Communication and Technology, 13-02-12)

Challenges experienced by the clinical team during the conduct of HIV vaccine clinical trials in Kenya

Omosa-Manyonyi, G; Jaoko, WG; Wakasiaka, S; Bwayo, J; Ndinya-Achola, J; Schmidt, C; Bhatt, K; Ogutu, H; K’Owino, D; Dally, L; Malogo, R; Fast, P (University of NairobiSchool of Medicine, 2005)

HIV vaccine clinical trials enrollment and retention: Experience from Kenya AIDS Vaccine Initiative

Omosa-Manyonyi, G; Jaoko, WG; Wakasiaka, S; Bwayo, J; Anzala, AO; Schmidt, C; Oyaro, M; Ogutu, H; Farah, B; Nyange, J; Bender, B; Odada, J; Fast, P; Verlinde, C (University of NairobiSchool of Medicine, 2005)

Out of range laboratory values: a major reason for exclusion from a phase 1 HIV vaccine clinical trial

Jaoko, W; Manyonyi, GO; Bhatt, K; Anzala, AO; Ogutu, H; Ndambuki, R; Wakasiaka, S; Farah, BM; Ogola, S; Indangasi, J; Onyango, J; Nyange, J; Ndinya-Achola, J; Thomson, H; Gilmour, J; Than, S; Komaroff, W; Kambili, C; Fast, P; Bwayo, JJ (University of NairobiSchool of Medicine, 2006)

Safety and immunogenicity of the VRC recombinant multiclade HIV-1 adenoviral vector vaccine alone or in combination with the VRC multiclade HIV-1 DNA plasmid vaccine in healthy African adults.

ayitenkore, K; Omosa-Manyonyi, G; Bwayo, J; Karita, E; Jaoko, WG; Schmidt, C; Gilmour, J; Boaz, M; Than, S; Graham, B (University of NairobiSchool of Medicine, 2007)

Safety and immunogenicity of the VRC recombinant multiclade HIV-1 adenoviral vector vaccine alone or in combination with the VRC multiclade HIV-1 DNA plasmid vaccine in healthy African adults (2009).

Omosa-Manyonyi, G; Jaoko, W; Anzala, O; Ogutu, H; Ndambuki, R; Wakasiaka, S; Malogo, R; Kayitenkore, K; Karita, E; Schmidt, C; Fast, P; Komaroff, W; Cooper, A; Boaz, M; Gilmour, J; Dally, L; Ho, M; Smith, C; Graham, B (University of NairobiSchool of Medicine, 2009)

Characteristics of a cohort of Kenyans with neutralizing antibodies against HIV infection

Omosa-Manyonyi, Gloria; Walter, Jaoko; Omu, Anzala; Hilda, Ogutu; Rose, Ndambuki; Sabina, Wakasiaka; Priscah, Wawire; Roselyn, Malogo; Fred, Oyugi; Samuel, Kazungu; Desmond, K’Owino; Bashir, Farah; Micah, Oyaro; Jackton, Indangasi; Simon, Ogola; James, Onyango; Jacky, Nyange; Tony, Tarragona; Melissa, Simek; Jennifer, Lehrman; Fran, Priddy; Patricia, Fast (University of NairobiSchool of Medicine, 2010)

Mucosal specimen collection in Africa: preliminary results of a pilot study for use in future HIV vaccine trials

Omosa, Gloria; Bashir, Farah; Harriet, H. Park; Alethea, Cope; Phil, Bergin; Paramesh, Chetty; Pat, Fast; Robin, Shattock; Gwynneth, Stevens; Josephine, Cox; Pauli, N. Amornkul; Jill, Gilmour; Omu, Anzala (University of NairobiSchool of Medicine, 2010)

Uptake and tolerability of repeated mucosal specimen collection in two Phase 1 AIDS preventive vaccine trials in Kenya

Gaudensia, Mutua; Omosa, Gloria; Harriet, Park; Phil, Bergin; Dagna, Laufer; Pauli, Amornkul; Jennifer, Lehrman; Pat, Fast; Jill, Gilmour; Omu, Anzala; Bashir, Farah (University of NairobiSchool of Medicine, 2012)

Co-administration of an adjuvanted HIV-1 Gag-Pol-Nef fusion protein (F4/AS01) and Adenovirus-35 Gag-RT-Int-Nef (Ad35-GRIN) is well tolerated and induces potent, polyfunctional CD4+ and CD8+ T cell responses.

Patricia, Bourguignon; Josephine, Cox; Peter, Hayes; Juliet, Mpendo; Omosa-Manyonyi, Gloria; Eugene, Ruzagira; Elwyn, Chomba; Len, Dally; François, Roman; Frances, Pridd (University of NairobiSchool of Medicine, 2013)

Conference/ Workshop/ Seminar/ Proceedings: Recent submissions

CD4+ and CD8+lymphocyte distribution among healthy Kenyans

Reasons for declining enrolment among eligible volunteers in a phase II HIV vaccine trial in Kenya

Safety profile of DNA and MVA HIV preventive vaccines

Income Inequality in Kenya: Some Technical Perspectives. Policy Paper prepared for Society for International Development, Nairobi

Safety and immunogenicity of DNA and MVA HIVA vaccines in Phase-1 vaccine trials in Nairobi, Kenya

Training Facilitators of Examinations Workshop for the School of Biological Sciences

Challenges experienced by the clinical team during the conduct of HIV vaccine clinical trials in Kenya

HIV vaccine clinical trials enrollment and retention: Experience from Kenya AIDS Vaccine Initiative

Out of range laboratory values: a major reason for exclusion from a phase 1 HIV vaccine clinical trial

Safety and immunogenicity of the VRC recombinant multiclade HIV-1 adenoviral vector vaccine alone or in combination with the VRC multiclade HIV-1 DNA plasmid vaccine in healthy African adults.

Safety and immunogenicity of the VRC recombinant multiclade HIV-1 adenoviral vector vaccine alone or in combination with the VRC multiclade HIV-1 DNA plasmid vaccine in healthy African adults (2009).

Characteristics of a cohort of Kenyans with neutralizing antibodies against HIV infection

Mucosal specimen collection in Africa: preliminary results of a pilot study for use in future HIV vaccine trials

Uptake and tolerability of repeated mucosal specimen collection in two Phase 1 AIDS preventive vaccine trials in Kenya

Co-administration of an adjuvanted HIV-1 Gag-Pol-Nef fusion protein (F4/AS01) and Adenovirus-35 Gag-RT-Int-Nef (Ad35-GRIN) is well tolerated and induces potent, polyfunctional CD4+ and CD8+ T cell responses.

The 8th Pan African Early Reading

Comparative and International Education Society (CIES) Annual Conference

The Humanitarian Partnership Conference

Curriculum Review Workshop

4th International Conference of the African Association of Agricultural Economists

Conference/ Workshop/ Seminar/ Proceedings: Recent submissions

CD4+ and CD8+lymphocyte distribution among healthy Kenyans ﻿

Reasons for declining enrolment among eligible volunteers in a phase II HIV vaccine trial in Kenya ﻿

Safety profile of DNA and MVA HIV preventive vaccines ﻿

Income Inequality in Kenya: Some Technical Perspectives. Policy Paper prepared for Society for International Development, Nairobi ﻿

Safety and immunogenicity of DNA and MVA HIVA vaccines in Phase-1 vaccine trials in Nairobi, Kenya ﻿

Training Facilitators of Examinations Workshop for the School of Biological Sciences ﻿

Challenges experienced by the clinical team during the conduct of HIV vaccine clinical trials in Kenya ﻿

HIV vaccine clinical trials enrollment and retention: Experience from Kenya AIDS Vaccine Initiative ﻿

Out of range laboratory values: a major reason for exclusion from a phase 1 HIV vaccine clinical trial ﻿

Safety and immunogenicity of the VRC recombinant multiclade HIV-1 adenoviral vector vaccine alone or in combination with the VRC multiclade HIV-1 DNA plasmid vaccine in healthy African adults. ﻿

Safety and immunogenicity of the VRC recombinant multiclade HIV-1 adenoviral vector vaccine alone or in combination with the VRC multiclade HIV-1 DNA plasmid vaccine in healthy African adults (2009). ﻿

Characteristics of a cohort of Kenyans with neutralizing antibodies against HIV infection ﻿

Mucosal specimen collection in Africa: preliminary results of a pilot study for use in future HIV vaccine trials ﻿

Uptake and tolerability of repeated mucosal specimen collection in two Phase 1 AIDS preventive vaccine trials in Kenya ﻿

Co-administration of an adjuvanted HIV-1 Gag-Pol-Nef fusion protein (F4/AS01) and Adenovirus-35 Gag-RT-Int-Nef (Ad35-GRIN) is well tolerated and induces potent, polyfunctional CD4+ and CD8+ T cell responses. ﻿

The 8th Pan African Early Reading ﻿

Comparative and International Education Society (CIES) Annual Conference ﻿

The Humanitarian Partnership Conference ﻿

Curriculum Review Workshop ﻿

4th International Conference of the African Association of Agricultural Economists ﻿

CD4+ and CD8+lymphocyte distribution among healthy Kenyans

Reasons for declining enrolment among eligible volunteers in a phase II HIV vaccine trial in Kenya

Safety profile of DNA and MVA HIV preventive vaccines

Income Inequality in Kenya: Some Technical Perspectives. Policy Paper prepared for Society for International Development, Nairobi

Safety and immunogenicity of DNA and MVA HIVA vaccines in Phase-1 vaccine trials in Nairobi, Kenya

Training Facilitators of Examinations Workshop for the School of Biological Sciences

Challenges experienced by the clinical team during the conduct of HIV vaccine clinical trials in Kenya

HIV vaccine clinical trials enrollment and retention: Experience from Kenya AIDS Vaccine Initiative

Out of range laboratory values: a major reason for exclusion from a phase 1 HIV vaccine clinical trial

Safety and immunogenicity of the VRC recombinant multiclade HIV-1 adenoviral vector vaccine alone or in combination with the VRC multiclade HIV-1 DNA plasmid vaccine in healthy African adults.

Safety and immunogenicity of the VRC recombinant multiclade HIV-1 adenoviral vector vaccine alone or in combination with the VRC multiclade HIV-1 DNA plasmid vaccine in healthy African adults (2009).

Characteristics of a cohort of Kenyans with neutralizing antibodies against HIV infection

Mucosal specimen collection in Africa: preliminary results of a pilot study for use in future HIV vaccine trials

Uptake and tolerability of repeated mucosal specimen collection in two Phase 1 AIDS preventive vaccine trials in Kenya

Co-administration of an adjuvanted HIV-1 Gag-Pol-Nef fusion protein (F4/AS01) and Adenovirus-35 Gag-RT-Int-Nef (Ad35-GRIN) is well tolerated and induces potent, polyfunctional CD4+ and CD8+ T cell responses.

The 8th Pan African Early Reading

Comparative and International Education Society (CIES) Annual Conference

The Humanitarian Partnership Conference

Curriculum Review Workshop

4th International Conference of the African Association of Agricultural Economists